New imaging agents aim to spot colorectal cancer spread
NCT ID NCT03275974
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether special PET scans using glutamine and FSPG can better detect tumors in people with advanced colorectal cancer. Six participants received these imaging agents, and researchers compared the results to standard CT or MRI scans. The study was terminated early, so findings are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RAS WILD TYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test tell if cancer is really gone?
- Experimental combo targets Hard-to-Treat GI cancers
- New combo therapy shows promise in early trial for liver-metastatic colorectal cancer
- New telehealth program aims to ease daily struggles for advanced cancer patients
- New drug duo shows promise for tough colorectal cancer